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Scheme S1. Synthesis of (a) hydrazide 10; and (b) achylhydrazones 2–9. 
 
Figure S1. Schematic representation of the predicted binding modes of acylhydrazone-
based inhibitors 1–9 in the active site of the endothiapepsin. These binding modes are the 
result of a docking run using the FlexX docking module with 30 poses and represent the 
top-scoring pose after HYDE scoring and careful visual inspection to exclude poses with 
significant inter- or intra-molecular clash terms or unfavorable conformations. The figure 




1. Experimental Procedures 
1.1. (S,E)-2-Amino-3-(1H-indol-3-yl)-N′-(4-(trifluoromethyl)benzylidene)propanehydrazide (2) 
The acylhydrazone 2 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide (10) (408 mg, 1.87 mM) and 4-trifluoromethyl-benzaldehyde 11 (306 µL, 2.24 mM). 
After purification, the acylhydrazone 2 was obtained as a mixture of E and Z isomers (E:Z = 64:36) as 
a white solid (365 mg, 52%). m.p. 187–190 °C; α[ ]D20 = +53.7 (c = 0.114 in MeOH); 1H NMR (400 MHz, 
CD3OD) δ = 8.03 (s, 1H, E), 7.92 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H, Z), 7.70 (d, J = 8.2 Hz, 1H),  
7.67–7.63 (m, 2H), 7.62 (s, 1H), 7.34 (d, J = 8.1 Hz, 1H, E), 7.24 (d, J = 8.1 Hz, 1H, Z), 7.15–7.06  
(m, 2H), 7.05–6.97 (m, 1H), 4.74 (t, J = 6.7 Hz, 1H, Z), 3.73 (t, J = 6.7 Hz, 1H, E), 3.29–3.22 (m, 1H), 
3.17–3.07 (m, 1H); 13C NMR (101 MHz, CD3OD) δ = 178.5, 174.5, 148.2, 144.1, 139.3, 138.2, 136.3, 
129.2, 128.8, 124.7 (d, J = 25.9 Hz), 124.86, 124.61, 122.50 (d, J = 5.5 Hz), 119.8 (d, J = 17.7 Hz), 
119.5 (d, J = 9.2 Hz), 112.4, 111.3, 111.0, 56.4, 52.7, 32.5 (d, J = 13.5 Hz); IR (cm–1): 3283 (br), 3058, 
2920, 1671, 1455, 743; 19F NMR (376 MHz, CD3OD) δ = −64.31, −64.39; HRMS (ESI) calculated for 
C19H17F3N4O [M + H]+: 375.1427, found: 375.1431; Elemental analysis, calculated for C19H17F3N4O 
(%): C 60.96, H 4.58, N 14.97. found: C 60.45, H 4.54, N 14.64. 
 
Scheme S2. Structure of (S,E)-2-amino-3-(1H-indol-3-yl)-N′-(4-(trifluoromethyl)benzylidene) 
propanehydrazide (2). 
1.2. (S,E)-2-Amino-3-(1H-indol-3-yl)-N′-(3-(trifluoromethyl)benzylidene)propanehydrazide (3) 
The acylhydrazone 3 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide (10) (403 mg, 1.85 mM) and 3-trifluoromethyl-benzaldehyde 12 (297 µL, 2.22 mM). 
After purification, the acylhydrazone 3 was obtained as a mixture of E and Z isomers (E:Z = 60:40) as 
a white solid (332 mg, 48%). m.p. 67–71 °C; α[ ]D20  = +39.1 (c = 0.097 in MeOH); 1H NMR (400 MHz, 
CD3OD): δ = 8.08 (s, 1H, E), 8.00 (s, 1H, E), 7.91 (s, 1H, Z), 7.89 (d, J = 4.1 Hz, 1H, E), 7.88 (s, 1H, 
Z), 7.71 (d, J = 7.7 Hz, 1H, Z), 7.68–7.47 (m, 3H), 7.31 (d, J = 8.1 Hz, 1H, E), 7.25 (d, J = 8.1 Hz, 1H, Z), 
7.12 (s, 1H, Z), 7.11 (s, 1H, E), 7.05 (dd, J = 15.1, 8.0 Hz, 1H), 7.01–6.95 (m, 1H), 3.76 (t, J = 6.8 Hz, 1H, 
E), 3.38–3.22 (m, 1H), 3.16–3.06 (m, 1H); 13C NMR (101 MHz, CD3OD): δ = 176.0, 173.8, 148.4, 
144.9, 138.2 (d, J = 8.5 Hz), 136.5 (d, J = 15.1 Hz), 133.8, 132.3, 130.7, 130.7 (d, J = 210.9 Hz), 130.7, 
128.7, 128.6, 127.7 (dd, J = 9.5, 5.8 Hz), 127.5 (dd, J = 7.8, 4.0 Hz), 125.1 (dd, J = 7.8, 3.8 Hz), 124.4, 
122.6, 122.5, 120.0, 119.9, 119.4, 119.1, 112.4, 112.3, 110.7, 110.2, 56.2, 52.5, 32.1, 31.1, 25.3; 19F 
NMR (376 MHz, CDCl3): δ = −62.82; IR (cm–1): 3332 (br), 2497 (br), 1668, 1326, 1120; HRMS (ESI) 







Scheme S3. Structure of (S,E)-2-amino-3-(1H-indol-3-yl)-N′-(3-(trifluoromethyl)benzylidene) 
propanehydrazide (3). 
1.3. (S,E)-2-Amino-N′-(2-fluorobenzylidene)-3-(1H-indol-3-yl)propanehydrazide (4) 
The acylhydrazone 4 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide (10) (363 mg, 1.66 mM) and 2-fluorobenzaldehyde 13 (210 µL, 1.99 mM). After 
purification, the acylhydrazone 4 was obtained as a mixture of E and Z isomers (E:Z = 58:42) as  
a white solid (237 mg, 44%). m.p. 175–176 °C; α[ ]D20  = +75.5 (c = 0.200 in MeOH); 1H NMR (400 MHz, 
CD3OD) δ = 8.27 (s, 1H, E), 8.17–8.08 (m, 1H), 7.71 (d, J = 7.5 Hz, 1H), 7.68 (d, J = 3.4 Hz, 1H), 
7.67–7.60 (m, 1H), 7.49–7.39 (m, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.31–6.94 (m, 9H), 4.73 (t, J = 6.6 Hz, 
1H, Z), 3.72 (t, J = 6.6 Hz, 1H, E), 3.26 (m, 1H), 3.17–3.00 (m, 1H); 13C NMR (101 MHz, CD3OD)  
δ = 178.1, 174.2, 164.2, 161.7, 142.7, 139.1, 139.0, 138.2, 133.4 (d, J = 8.6 Hz), 132.8 (d, J = 8.5 Hz), 
128.8 (d, J = 9.5 Hz), 128.7, 128.1, 125.7, 124.7 (d, J = 16.2 Hz), 123.0, 122.5, 119.8 (d, J = 15.3 Hz), 
119.5, 116.7 (dd, J = 21.2, 8.6 Hz), 112.4, 111.2, 110.9, 56.3, 52.6, 32.3; 19F NMR (376 MHz, 
CD3OD) δ = −123.17 (m), −123.34 (m); IR (cm−1): 3286 (br), 3056, 2921, 1673, 1615, 1455, 1357, 
1238, 743; HRMS (ESI) calculated for C18H17FN4O [M + H]+: 325.1459, found: 325.1465. 
 
Scheme S4. Structure of (S,E)-2-amino-N′-(2-fluorobenzylidene)-3-(1H-indol-3-yl)propanehydrazide (4). 
1.4. (S,Z)-2-Amino-N′-(2-hydroxy-3-methylbenzylidene)-3-(1H-indol-3-yl)propanehydrazide (5) 
The acylhydrazone 5 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide (10) (410 mg, 1.88 mM) and 2-hydroxy-3-methylbenzaldehyde 14 (273 µL, 2.25 mM). 
After purification, the acylhydrazone 5 was obtained as a mixture of E and Z isomers (E:Z = 93:7) as  
a yellow solid (246 mg, 39%). m.p. 86–90 °C; α[ ]D20  = +103.0 (c = 0.146 in MeOH); 1H NMR  
(400 MHz, CD3OD) δ = 8.28 (s, 1H, E), 8.11 (s, 1H, Z), 7.97 (s, 1H, E), 7.63 (d, J = 8.0 Hz, 1H), 7.34 
(d, J = 8.0 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 7.13 (s, 1H), 7.11–7.05 (m, 2H), 7.04–6.98 (m, 1H), 6.81 
(dd, J = 10.0, 5.1 Hz, 1H), 3.72 (t, J = 6.7 Hz, 1H, Z), 3.27 (dd, J = 14.2, 6.8 Hz, 1H), 3.12 (dd,  
J = 14.2, 6.8 Hz, 1H), 2.26 (s, 3H); 13C NMR (101 MHz, CD3OD) δ = 173.3, 157.6, 152.6, 149.6, 
138.1, 134.0, 130.0, 128.7, 126.9, 124.8, 122.5, 120.1, 119.9, 119.4, 118.2, 112.3, 111.0, 56.3, 32.4, 
15.7; IR (cm−1): 3351 (br), 2475 (br), 2216, 2071, 1120, 972; HRMS (ESI) calculated for C19H20N4O2 






Scheme S5. Structure of (S,Z)-2-amino-N′-(2-hydroxy-3-methylbenzylidene)-3-(1H-indol-3-yl) 
propanehydrazide (5). 
1.5. (S,E)-2-Amino-N′-(2-bromobenzylidene)-3-(1H-indol-3-yl)propanehydrazide (6) 
The acylhydrazone 6 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide (10) (345 mg, 1.58 mM) and 2-bromobenzaldehyde 15 (220 µL, 1.89 mM). After 
purification, the acylhydrazone 6 was obtained as a mixture of E and Z isomers (E:Z = 55:45) as  
a white solid (315 mg, 52%). m.p. 80–86 °C; α[ ]D20  = +54.8 (c = 0.091 in MeOH); 1H NMR (400 MHz, 
CD3OD) δ = 7.98 (s, 1H, E), 7.92 (s, 1H, E), 7.83 (s, 1H, Z), 7.82 (s, 1H, Z), 7.68 (d, J = 6.0 Hz, 1H, E), 
7.66–7.61 (m, 1H), 7.56 (ddd, J = 7.9, 2.8, 1.8 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H, Z), 7.37–7.31 (m, 1H), 
7.31–7.26 (m, 1H), 7.13 (d, J = 4.3 Hz, 1H), 7.10–7.05 (m, 1H), 7.01 (t, J = 7.4 Hz, 1H), 4.77 (t,  
J = 7.7 Hz, 1H, Z), 3.73 (t, J = 6.7 Hz, 1H, E), 3.31–3.24 (m, 1H), 3.17–3.00 (m, 1H); 13C NMR (101 
MHz, CD3OD) δ = 177.4, 174.1, 148.3, 144.6, 138.2, 138.1, 137.7, 134.2, 134.0, 133.4, 131.6, 131.5, 
131.1, 130.3, 128.7, 127.7, 127.4, 124.8, 123.8, 123.5, 122.5, 122.5, 120.1, 119.9, 119.4, 119.3, 112.4, 
112.3, 110.9, 110.8, 56.3, 52.5, 32.3, 32.0; IR (cm−1): 3287 (br), 3056, 2920, 1673, 1561, 744; HRMS 
(ESI) calculated for C18H17BrN4O [M + H]+: 387.0638, found: 387.0639. 
 
Scheme S6. Structure of (S,E)-2-amino-N′-(2-bromobenzylidene)-3-(1H-indol-3-yl)propanehydrazide (6). 
1.6. (S,E)-2-Amino-3-(1H-indol-3-yl)-N′-(2-methylbenzylidene)propanehydrazide (7) 
The acylhydrazone 7 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide (10) (200 mg, 0.92 mM) and o-tolualdehyde 16 (160 µL, 1.38 mM). After purification, 
the acylhydrazone 7 was obtained as a mixture of E and Z isomers (E:Z = 60:40) as a white solid  
(130 mg, 44%). m.p. 96–98 °C; α[ ]D20  = +38.4 (c = 0.208 in MeOH); 1H NMR (400 MHz, CD3OD)  
δ = 8.29 (s, 1H, E), 8.23 (s, 1H, Z), 7.95 (d, J = 7.5 Hz, 1H, E), 7.70 (d, J = 7.6 Hz, 1H, Z), 7.68–7.59  
(m, 1H), 7.37–7.25 (m, 2H), 7.25–7.15 (m, 2H), 7.13 (d, J = 5.7 Hz, 1H), 7.11–7.05 (m, 1H),  
7.05–6.94 (m, 1H), 4.73 (dd, J = 7.7, 5.5 Hz, 1H, Z), 3.71 (t, J = 6.8 Hz, 1H, E), 3.31–3.21 (m, 1H), 
3.16–3.01 (m, 1H), 2.44 (s, 1H), 2.38 (s, 2H); 13C NMR (101 MHz, CDCl3) δ = 171.0, 147.0, 137.3, 
136.5, 136.4, 131.8, 131.1, 130.8, 130.3, 130.1, 127.6, 127.1, 126.4, 123.7, 123.5, 122.1, 122.1, 119.7, 
119.4, 119.1, 118.9, 111.5, 55.3, 52.1, 30.7, 25.4, 19.9, 19.5; IR (cm−1): 3300 (br), 3057, 2923, 2461 







Scheme S7. Structure of (S,E)-2-amino-3-(1H-indol-3-yl)-N′-(2-methylbenzylidene)propanehydrazide (7). 
1.7. (S,E)-2-Amino-N′-(2,6-dimethylbenzylidene)-3-(1H-indol-3-yl)propanehydrazide (8) 
The acylhydrazone 8 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide (10) (136 mg, 0.62 mM) and 2,6-dimethylbenzaldehyde 17 (114 mg, 0.85 mM). 
After purification, the acylhydrazone 8 was obtained as a mixture of E and Z isomers (E:Z = 42:50) as  
a white solid (76 mg, 37%). m.p. 90–97 °C; α[ ]D20  = +28.6 (c = 0.084 in MeOH); 1H NMR (400 MHz, 
CD3OD) δ = 8.35 (s, 1H, E), 8.30 (s, 1H, Z), 7.64 (d, J = 8.0 Hz, 1H, Z), 7.52 (d, J = 8.1 Hz, 1H, E),  
7.35 (d, J = 8.0 Hz, 1H, Z), 7.30 (d, J = 8.1 Hz, 1H, E), 7.23–6.99 (m, 6H), 6.89–6.82 (m, 1H, E),  
4.65 (dd, J = 7.6, 5.3 Hz, 1H, E), 3.72 (t, J = 6.8 Hz, 1H, Z), 3.30–3.21 (m, 1H), 3.18–3.04 (m, 1H),  
2.43 (s, 3H), 2.37 (s, 3H); 13C NMR (101 MHz, CD3OD) δ = 177.1, 173.6, 150.2, 146.6, 138.9, 138.8, 
138.2, 132.4, 132.2, 130.2, 130.1, 129.8, 129.5, 128.8, 128.8, 124.9, 124.7, 122.5, 122.4, 119.9, 119.7, 
119.5, 112.3, 110.9, 110.8, 56.3, 52.9, 32.5, 31.5, 21.5, 21.1; IR (cm−1): 3283 (br), 3058, 2971, 2922, 
1672, 1334, 1237, 742; HRMS (ESI) calculated for C20H22N4O [M + H]+: 335.1866, found: 335.1870. 
 
Scheme S8. Structure of (S,E)-2-amino-N′-(2,6-dimethylbenzylidene)-3-(1H-indol-3-yl)propanehydrazide (8). 
1.8. (S,E)-2-Amino-N′-benzylidene-3-(1H-indol-3-yl)propanehydrazide (9) 
The acylhydrazone 9 was synthesized according to GP by using (S)-2-amino-3-(1H-indol-3-yl) 
propanehydrazide 10 (213 mg, 0.98 mM) and benzaldehyde 18 (120 µL, 1.18 mM). After purification, 
the acylhydrazone 9 was obtained as a mixture of E and Z isomers (E:Z = 52:48) as a white solid  
(117 mg, 39%). m.p. 146–149 °C; α[ ]D20  = +62.3 (c = 0.132 in MeOH); 1H NMR (400 MHz, CD3OD) 
δ = 7.92 (s, 1H, E), 7.86 (s, 1H, Z), 7.69–7.55 (m, 3H), 7.38–7.26 (m, 4H), 7.11–6.95 (m, 3H),  
4.76–4.69 (m, 1H, Z), 3.71 (t, J = 6.8 Hz, 1H, E), 3.29–3.21 (m, 1H), 3.11–2.98 (m, 1H); 13C NMR  
(101 MHz, CD3OD) δ = 177.3, 173.8, 150.3, 146.5, 138.0, 135.3, 135.2, 131.5, 131.1, 129.7, 128.7, 
128.2, 124.8, 122.5, 119.9, 119.8, 119.4, 56.1, 52.5, 32.2, 31.8; IR (cm−1): 3280 (br), 3058, 2922, 
1670, 1455, 743, 692; HRMS (ESI) calculated for C18H18N4O [M + H]+: 307.1553, found: 307.1557. 
 








2. NMR Spectra 
 
Figure S2. 1H NMR spectrum of compound 2. 
 





Figure S4. 19F NMR spectrum of compound 2. 
 





Figure S6. 13C NMR spectrum of compound 3. 
 





Figure S8. 1H NMR spectrum of compound 4. 
 





Figure S10. 19F NMR spectrum of compound 4. 
 





Figure S12. 13C NMR spectrum of compound 5. 
 





Figure S14. 13C NMR spectrum of compound 6. 
 





Figure S16. 13C NMR spectrum of compound 7. 
 





Figure S18. 13C NMR spectrum of compound 8. 
 





Figure S20. 13C NMR spectrum of compound 9. 
3. HPLC Chromatograms 
 





Figure S22. Chromatogram of compound 3. 
 





Figure S24. Chromatogram of compound 5. 
 





Figure S26. Chromatogram of compound 7. 
 





Figure S28. Chromatogram of compound 9. 
